The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond
Cell and Gene Therapy Insights · 14.07.2026 · 12 (5) · 599–605
DOI: 10.18609/cgti.2026.073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 14.07.2026. Verfasst von Eddie Tan Han Pin. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Wil Rich, Editor, Cell & Gene Therapy Insights, speaks with Eddie Tan Han Pin, Assistant Professor, Centre of Regulatory Excellence, Duke‑NUS Medical School, about his career journey from molecular cancer biology through GMP manufacturing and regulatory science into health policy, the evolving regulatory landscape for cell and gene therapies in Singapore and the Asia‑Pacific region, the role of regulatory reliance frameworks in broadening equitable patient access, and the transformative potential of AI across the cell and gene therapy development value chain.
Zitieren
APA
Pin, E. T. H. (2026). The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond. Cell and Gene Therapy Insights, 12(5), 599–605. https://doi.org/10.18609/cgti.2026.073
Vancouver
Pin ETH. The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond. Cell and Gene Therapy Insights. 2026;12(5):599–605. doi:10.18609/cgti.2026.073
BibTeX
@article{Pin2026,
author = {Pin, Eddie Tan Han},
title = {The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {5},
pages = {599–605},
doi = {10.18609/cgti.2026.073}
}
EUVIMED